Some information:
MedClean Technologies, Inc. engages in the design, sale, installation, and servicing of onsite turnkey systems to treat regulated medical waste. It provides MedClean series systems as solutions to incineration or off site hauling of untreated medical waste, and to various other alternative treatment technologies and methodologies. The company’s MedClean system employs various equipment and machinery, including an autoclave vessel to sterilize the medical waste; a shredding device, the MedClean Shredder, to convert sterilized waste material into confetti-like material qualifying the end product as municipal solid waste; an AutoTouch control station with software and hardware components that integrate and bundle operating and data recording functions into a system for conversion and disposal of medical waste; a material transporter to mechanically transport the processed waste from shredder to the municipal solid waste compacting dumpster; and a QuietCart transport cart system to facilitate a single source containerization of the infectious waste from generation, sterilization, processing, and return for refill. It markets its MedClean systems directly to waste generators, such as hospitals, nursing homes, clinics, medical groups, county or city health departments, laboratories, physicians, dentists, and veterinarians in private practice. The company was formerly known as Aduromed Industries, Inc. and changed its name to Medclean Technologies, Inc. in January 2009. MedClean Technologies, Inc. is based in Bethel, Connecticut.
Why buy? Their cash flow is amazing. Link: http://finance.yahoo.com/q/cf?s=MCLN.OB
Total Cash Flow From Operating Activities is positive, positive net income, and they are paying back liabilities.
They are a real company!!! They have a great website (http://www.aduromed.com/) and it has a rare opportunity to emerge as breakout player in the multi-billion dollar regulated medical waste market (http://finance.yahoo.com/news/MedClean-Technologies-OTC-iw-2317095593.html?x=0&.v=1).
Check them out! It is truly a great stock. The company is currently trading at $0.033 (12/23/09).
Wednesday, December 23, 2009
BioElectronics
Have you ever heard of a fully recording penny stock? Well exempt from Citigroup, Freddie Mac, Fannie Mae, Sirius Satellite Radio, it is pretty hard. Believe it or not, I have found two companies that are fully recording. This blog is about BioElectronics (BIEL.PK) and the next will be about the other company. BioElectronics company is a fully reporting company. I have many shares with them.
Here are some reasons why I like this company:
In December 2004 the Company received ISO and CE (European Common Market) certification. In 2005 Health Canada, (Canada's FDA) approved ActiPatch Therapy: for the relief of pain in muscosketal complaints.
In April 2005, the Company established an Orthopedic Group, a direct response sales organization, and its design and manufacturing operations in Westlake Village, California. In 2007 the Company shut down the Orthopedic Group, moved all operations to the home office and transferred manufacturing offshore.
In early 2008 the Company redesigned its product, manufacturing and established new disease specific products and distinct medical and retail product lines. It also shifted its attention to international sales.
The company also commenced a series of double-blind clinical trials to be conducted in conjunction with leading schools of podiatry and selected clinics to document the effects of ActiPatch on treating plantar fasciitis [heel pain]. The studies in started in March 2006. The Principal Investigator for the study is Dr. William Van der Reis, a Board Certified Orthopedic Surgeon and sports medicine specialist.
The primary motivation for continued clinical trials is to obtain additional FDA approved therapeutic indications for existing and future products and to facilitate faster diffusion of the Companies medical product line by the medical community. Securing FDA approval is central to market entry and product acceptance. Below are listed currently planned clinical studies.
Ankle Sprains: This study will use Grade I and II ankle sprains (no gross instability) as the entry criteria. The patients will be randomly assigned to two treatment groups after initial biometric measurement of inversion and eversion power, (swelling around the injury) and recorded photographic documentation of the injury. Five data points, including the first visit point, will monitor the rate of recovery. The monitoring will include swelling circumferential measurements at the level of injury, photography, and repeated inversion and eversion power measurements. Digital scales will assess total weight bearing capability. The targeted claim will document an accelerated return to normal power and weight bearing capability on the actively treated ankle injury as compared to the uninjured ankle.
Heel Pain: Chief Investigator, Joel Brook, D.P.M. - The Heel Pain study is a randomized study with both a placebo and control study group. Each patient will be asked to rate morning pain prior to treatment on a severity scale of 1 to 10 (10 being intolerable and 1 being absence of pain). Patients will also be evaluated to determine weight bearing tolerance on the affected heal, and the approximate percentage of the total weight borne. The daily therapeutic treatment regime of 8 hours will be conducted on each patient during
normal sleep.
C-Sections: Chief Investigator, Chad Simmons, M.D. Dr. Simmons is chief of obstetrics and gynecology at the Methodist Hospital in Dallas. The hospital has a large residency program, which will facilitate completion of the 120 patient study within 4 months. The overall hypothesis of the study is that pulsed electromagnetic therapy will ameliorate the inflammatory effects of edema and pain without the adverse effects typically experience by standard pharmacological therapy.
Breast Augmentations: Dr. David Genecov will be the chief investigator Dr. Genecov with 11 other plastic surgical sites will each treat 10 patients with either an active or placebo device. The goal is to obtain results prior to an October meeting where Dr. Genecov is scheduled to present the results. The hypothesis of the study is the measure the comparative reduction of pain and edema between the active and placebo devices.
Blepharoplasty: This new blepharoplasty study is to test the new eye devices. The goal of the study is to compare the efficacy of the device to placebo devices in decreasing the edema, erythema, ecchymosis, and discomfort associated with the surgical recovery. The physician and the patient will evaluate efficacy in one week. The lead investigators are Dr. Jill Foster, Clinical Assistant Professor and Dr. Craig Czyz, Chief Resident at The Ohio State University Medical Center, Department of Ophthalmology.
In 2000, BioElectronics gained rights to the technology and patents supporting the development of the current product line. Prior to that time the previous owners of the technology and patents had invested over $4.65 million in electronic engineering prototypes, production runs, and in confirming clinical studies. BioElectronics subsequently filed with the US Food and Drug Administration for market clearance in April 2000.
The Company was granted its first approval from the FDA under a 510k in August 2002. Prior to FDA approval and the establishment of its research and development group, PAW, LLC (Andrew Whelan's wife and children) paid and expensed the cost of development.
In 2003, BioElectronics redesigned the ActiPatch product to reduce its size and costs to manufacture and developed several new products. In March 2004, the Company sold 5,020,000 shares of common stock and the Company's stock was listed on the Pink Sheets.
The Company was granted its first approval from the FDA under a 510k in August 2002. Prior to FDA approval and the establishment of its research and development group, PAW, LLC (Andrew Whelan's wife and children) paid and expensed the cost of development.
In 2003, BioElectronics redesigned the ActiPatch product to reduce its size and costs to manufacture and developed several new products. In March 2004, the Company sold 5,020,000 shares of common stock and the Company's stock was listed on the Pink Sheets.
In December 2004 the Company received ISO and CE (European Common Market) certification. In 2005 Health Canada, (Canada's FDA) approved ActiPatch Therapy: for the relief of pain in muscosketal complaints.
In April 2005, the Company established an Orthopedic Group, a direct response sales organization, and its design and manufacturing operations in Westlake Village, California. In 2007 the Company shut down the Orthopedic Group, moved all operations to the home office and transferred manufacturing offshore.
In early 2008 the Company redesigned its product, manufacturing and established new disease specific products and distinct medical and retail product lines. It also shifted its attention to international sales.
About the products:
There are 5 products the company offers. All of them are listed and described on their website:
Some more infomation:
In 2006, the Company and the Lahey Clinic jointly announced a three-year program to study the effects of ActiPatch Therapy on a variety of soft tissue injuries and related medical conditions. The internationally renowned Lahey Clinic of Boston, whose faculty is affiliated with the Medical Schools of Harvard and Tufts, has committed to initiating a number of double-blind clinical studies on ActiPatch Therapy in the areas of plastic surgery, orthopedics and chronic wound care. Results from these clinical trials will be submitted to the United States Food and Drug Administration (the FDA) for expanded indications for the use of ActiPatch Therapy.
The company also commenced a series of double-blind clinical trials to be conducted in conjunction with leading schools of podiatry and selected clinics to document the effects of ActiPatch on treating plantar fasciitis [heel pain]. The studies in started in March 2006. The Principal Investigator for the study is Dr. William Van der Reis, a Board Certified Orthopedic Surgeon and sports medicine specialist.
The primary motivation for continued clinical trials is to obtain additional FDA approved therapeutic indications for existing and future products and to facilitate faster diffusion of the Companies medical product line by the medical community. Securing FDA approval is central to market entry and product acceptance. Below are listed currently planned clinical studies.
Ankle Sprains: This study will use Grade I and II ankle sprains (no gross instability) as the entry criteria. The patients will be randomly assigned to two treatment groups after initial biometric measurement of inversion and eversion power, (swelling around the injury) and recorded photographic documentation of the injury. Five data points, including the first visit point, will monitor the rate of recovery. The monitoring will include swelling circumferential measurements at the level of injury, photography, and repeated inversion and eversion power measurements. Digital scales will assess total weight bearing capability. The targeted claim will document an accelerated return to normal power and weight bearing capability on the actively treated ankle injury as compared to the uninjured ankle.
Heel Pain: Chief Investigator, Joel Brook, D.P.M. - The Heel Pain study is a randomized study with both a placebo and control study group. Each patient will be asked to rate morning pain prior to treatment on a severity scale of 1 to 10 (10 being intolerable and 1 being absence of pain). Patients will also be evaluated to determine weight bearing tolerance on the affected heal, and the approximate percentage of the total weight borne. The daily therapeutic treatment regime of 8 hours will be conducted on each patient during
normal sleep.
C-Sections: Chief Investigator, Chad Simmons, M.D. Dr. Simmons is chief of obstetrics and gynecology at the Methodist Hospital in Dallas. The hospital has a large residency program, which will facilitate completion of the 120 patient study within 4 months. The overall hypothesis of the study is that pulsed electromagnetic therapy will ameliorate the inflammatory effects of edema and pain without the adverse effects typically experience by standard pharmacological therapy.
Breast Augmentations: Dr. David Genecov will be the chief investigator Dr. Genecov with 11 other plastic surgical sites will each treat 10 patients with either an active or placebo device. The goal is to obtain results prior to an October meeting where Dr. Genecov is scheduled to present the results. The hypothesis of the study is the measure the comparative reduction of pain and edema between the active and placebo devices.
Blepharoplasty: This new blepharoplasty study is to test the new eye devices. The goal of the study is to compare the efficacy of the device to placebo devices in decreasing the edema, erythema, ecchymosis, and discomfort associated with the surgical recovery. The physician and the patient will evaluate efficacy in one week. The lead investigators are Dr. Jill Foster, Clinical Assistant Professor and Dr. Craig Czyz, Chief Resident at The Ohio State University Medical Center, Department of Ophthalmology.
BioElectronics Distributer's:
Contacting BioElectronics:
4539 Metropolitan Ct.
Frederick, MD 21704
866-757-2284 Toll Free
301-874-4890 Phone
301-874-6935 Fax
Office Hours:
9 A.M. - 5 P.M. EST
E-mail: info@bielcorp.com
Frederick, MD 21704
866-757-2284 Toll Free
301-874-4890 Phone
301-874-6935 Fax
Office Hours:
9 A.M. - 5 P.M. EST
E-mail: info@bielcorp.com
Summing it up:
Why do I like them? They have potential. They are selling their product now on Amazon (http://www.amazon.com/s/ref=nb_ss?url=search-alias%3Daps&field-keywords=BioElectronics&x=0&y=0). They are awaiting FDA approval. Their Anti-Patch is better than Tylenol (http://finance.yahoo.com/news/BioElectronics-Technology-iw-3088384703.html?x=0&.v=1). Their products are selling overseas. Now the question is, why wouldn't it be approved by the FDA even if it is selling overseas?
They are awaiting OTCBB approval.
FDA approval will proballly in January. OTCBB listing should be within a couple of weeks.
The company is currently trading at $0.0499 (on 12/23/09).This is your choice to invest, not mine. I will not be responsible for any losses.
Tuesday, December 22, 2009
Raven Biofuels
The race to build the first next-generation cellulosic ethanol plants in the United States is on! The plants will be built all over the U.S. and will churn out biofuels made from waste, plant byproducts and woody energy crops. Not an easy task. Government initiatives to increase the use of renewable and alternative fuels in the transportation sector to are fueling the race, with grants subsidies and talks of tax breaks. Lets face it folks no-ones ready to store the cars in long term storage; automobiles and the engines they run on aren't exactly going away anytime soon. And that's why we all need an alternative. Companies are focusing on finding the right recipe to make the cellulosic ethanol production economically feasible. Biofuels are created by converting organic matters into fuel so that mankind can be supplied with energy. The biofuels represent alternative ways to stop using the fossil fuels which are already depleting for the near future. Biofuels include under this designation ethanol, derivatives of plants namely sugar cane, corn oils and vegetables. Nonetheless, not all products made from ethanol can be used to generate power. The agency catering for international energy has concluded that ethanol can be used to supply ten percent of the total amounts of gasoline necessary to mankind starting from 2025, and thirty percent of it until 2050. Until now, the percentage remains relatively low, at about two percent. Lets take a look.
Raven Biofuels International Corp (RVBF.PK)
RVBF was formed to address the unprecedented global demand for clean and renewable energy. The principle focus is production and distribution of high quality fuel-grade cellulosic ethanol. RVBF management has strong financial and operational backgrounds, long-standing relationships specific to the renewable energy sector and are transaction-driven executives capable of structuring and undertaking institutional financings. Raven represents a significant opportunity for investors.
RVBF is positioned for growth in the more evolved and, potentially, more profitable second wave of biofuel companies (cellulosic), or what experts are calling "Biofuels 2.0".
Raven Biofuels Technology
RVBF and its technology partners have been leading the charge to develop technologies and processes that will transform cellulosic waste biomass into renewable fuels. To date we have achieved the following milestones:
$24,000,000 invested in R&D
9 US patents in three principle areas; process patents for separating sugars to make ethanol and high value chemicals, fuel additives and diesel fuel mixtures.
21 International Patents Granted including Europe, Japan, China, India.
Extensive independent testing of technology since 1997 with conclusively positive results.
The technology that RVBF has chosen to commercialize is based on Acid Hydrolysis and further proprietary technology which can produce high value specialty chemicals from agriculture waste products, hence reducing the production cost of ethanol below $1.00 per gallon.
The technology is based on a two stage dilutive acid hydrolysis process. It essentially works by breaking down bio matter, such as wood chips, corn stover, and sugarcane bagasse into primary sugar streams that are then converted into a suite of chemicals including ethanol. RVBF management believes this technology is superior to other cellulosic production methods in use today.
Some analysts predict that alternative energies, thus biofuels will supply seven percent of total energy demands for transportation by 2030. Therefore, the energy market will definitely be affected in an irreversible way that will make institutions and government authorities unable to regulate the impact of biofuels. If the government nonetheless, agrees to subsidize firm and thus encourage the distribution of biofuels, then the eco-friendly alternative will stand more chances in becoming the norm.
Worldwide, there are more nations involved and committed to promoting the usage of biofuels against the usage of more traditional fuels.
These countries include Brazil, who occurs to be the biggest producer of ethanol of them all. It produces ethanol mainly from sugar, around half a billion gallons each year of ethanol production.
While it is the largest consumer of fuels on earth at the moment, the US is also the second largest country producing biofuels, just behind Brazil. Thus, the biofuel quantity produced by the European Union amounts for up to four million tons of biofuel. About eighty percent of the amount of biodiesel fuels coming from the EU is obtained from rapeseed; the rest of it comes from soybean oils and well as some palm oil quantity . These sources represent the remaining twenty percent of the production of biofuel in Europe.
_____________________________________________________
The promise of cellulosic ethanol and the problems with corn based ethanol production has been noted by the officials from the U.S. Department of Energy and officers of Fortune 500 Companies:
Secretary of Energy Samuel Bodman: "Although the situation is complex, the bottom line is that we need more energy from all sources. We must use fossil energy, which will continue to dominate world energy supplies for the next several decades at least. We must increase our use of currently available renewable energy technologies like solar and wind power and develop new ones like cellulosic ethanol, which could offer a more cost competitive alternative transportation fuel than ethanol currently produced from corn..."
Deputy Energy Secretary Clay Sell:
Secretary of Energy Samuel Bodman: "Although the situation is complex, the bottom line is that we need more energy from all sources. We must use fossil energy, which will continue to dominate world energy supplies for the next several decades at least. We must increase our use of currently available renewable energy technologies like solar and wind power and develop new ones like cellulosic ethanol, which could offer a more cost competitive alternative transportation fuel than ethanol currently produced from corn..."
Deputy Energy Secretary Clay Sell:
"I'm not going to predict what the price of corn is going to do, but I will tell you the future of biofuels is not based on corn"
Andy Karsner - Assistant Energy Secretary for Energy Efficiency and Renewable Energy:
Andy Karsner - Assistant Energy Secretary for Energy Efficiency and Renewable Energy:
"You mentioned a concern over the cost of food. Until now, most ethanol has been produced from corn. But President Bush.s Biofuels Initiative provides leadership and funding for developing what we call cellulosic ethanol - ethanol produced from non-edible portions of food and agricultural waste. The President.s Biofuels Initiative aims to make cellulosic ethanol cost competitive with gasoline by 2012 . and this isn.t just pie in the sky; we're funding major projects that will help get us there."
Beth Lowery, GM.s Vice President of Environment, Energy and Safety Policy:
Beth Lowery, GM.s Vice President of Environment, Energy and Safety Policy:
"We continue to believe that biofuels, specifically E85, is the most significant thing we can do in the near-term to offset future energy demands..We are on target to make 50 percent of our vehicles flex-fuel capable by 2012 providing the infrastructure is in place...
We believe ethanol used as fuel, not just as a gasoline additive, is the best near-term alternative to surging global demand for oil because ethanol is renewable and it reduces CO2 emissions compared to gasoline."
The analyst report noted that in the BioFuels Journal, GM stated that it would offer 18 flexible fuel vehicles (FFV) in the model year 2009, including a range of models in the Chevrolet, GMC, Cadillac, Hummer and Buick lines. GM vehicles represent approximately 3 million of the 7 million FFV in the U.S. The article also estimates that there are 1,600 E85 stations in the U.S., representing progress in the development of the requisite ethanol infrastructure.
_____________________________________________________
We believe ethanol used as fuel, not just as a gasoline additive, is the best near-term alternative to surging global demand for oil because ethanol is renewable and it reduces CO2 emissions compared to gasoline."
The analyst report noted that in the BioFuels Journal, GM stated that it would offer 18 flexible fuel vehicles (FFV) in the model year 2009, including a range of models in the Chevrolet, GMC, Cadillac, Hummer and Buick lines. GM vehicles represent approximately 3 million of the 7 million FFV in the U.S. The article also estimates that there are 1,600 E85 stations in the U.S., representing progress in the development of the requisite ethanol infrastructure.
_____________________________________________________
Raven Biofuels International Corp (RVBF.PK) could be a great play rolling into 2010, it's a hot sector with the wind at its back.
Put your limit orders in and your trailing stops to protect your downside. I will be getting more into this with all of you over the holidays. I know that some of you are new and it's key that you protect your capital when trading.
For more information please visit http://www.ravenbiofuels.com/
RVBF IS ON WATCH! Trade well and profit! The stock is currently trading at $0.12 (On 12/23/09).
Always consult with a professional and do your own research.
Happy Holidays and Best Regards
Put your limit orders in and your trailing stops to protect your downside. I will be getting more into this with all of you over the holidays. I know that some of you are new and it's key that you protect your capital when trading.
For more information please visit http://www.ravenbiofuels.com/
RVBF IS ON WATCH! Trade well and profit! The stock is currently trading at $0.12 (On 12/23/09).
Always consult with a professional and do your own research.
Happy Holidays and Best Regards
Subscribe to:
Posts (Atom)